Reuters logo
BRIEF-Transgene presents results of phase 1 part of METROmaJX trial
September 7, 2017 / 4:37 PM / 14 days ago

BRIEF-Transgene presents results of phase 1 part of METROmaJX trial

Sept 7 (Reuters) - TRANSGENE SA:

* ANNOUNCES RESULTS OF PHASE 1 PART OF METROMAJX TRIAL

* PHASE 2 PART OF THE TRIAL IS CURRENTLY ENROLLING PATIENTS

* PHASE 1 TRIAL RESULTS SHOWED THAT REGIMEN ASSOCIATING INTRAVENOUS INFUSION OF PEXA-VEC (JX-594) WITH LOW-DOSE CYCLOPHOSPHAMIDE WAS WELL-TOLERATED WITH NO DOSE LIMITING TOXICITY IN PATIENTS WITH SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below